Clive Dix, chief executive of , () brings Proactive up to speed on developments with the firm's portfolio of drug candidates.
They've recently presented some pre-clinical data at a leading industry conference which they say strengthens the evidence base backing the potential of the anti-addiction drug Orexin-1.
It's being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.
The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings plc named herein, including the promotion by the Company of C4X Discovery Holdings plc in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE